Phase 2 vs Phase 3 — Infectious Disease Deal Valuation Comparison

Phase 2 Median Upfront

$604M

Total: $2.3B

Phase 3 Median Upfront

$1.5B

Total: $4.1B

Stage Premium

79%

Phase 3 premium over Phase 2

Phase 2 Royalties

8.1%-16.3%

vs Phase 3: 11.6%-23.2%

Model Your Deal

Market Analysis

The Phase 2 to Phase 3 transition in infectious disease represents a significant value inflection point. Phase 3 deals carry a median total deal value of $4.1B compared to $2.3B at Phase 2, a 79% premium reflecting clinical de-risking. Upfront payments increase from $604M to $1.5B.

Deal structures shift as assets advance. Phase 2 deals allocate 26% to upfront and 74% to milestones, while Phase 3 deals shift to 36%/64%. Development milestones move from $376M to $263M, and royalty rates evolve from 8.1%-16.3% to 11.6%-23.2%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 2 to Phase 3 in infectious disease?

Phase 3 infectious disease deals command a 79% premium over Phase 2 in total deal value ($4.1B vs $2.3B). Upfronts increase from $604M to $1.5B, reflecting the de-risking value of clinical progression.

How do deal structures differ between Phase 2 and Phase 3 in infectious disease?

Phase 2 deals are more milestone-weighted (74% milestones), reflecting higher clinical risk. Phase 3 deals shift toward higher upfront allocations (36% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a infectious disease asset?

The optimal licensing window depends on strategic priorities. Phase 2 assets offer lower entry cost for licensees, while Phase 3 assets provide more certainty. The 79% premium from Phase 2 to Phase 3 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included